Latest Centocor Stories

NEW BRUNSWICK, N.J., Jan. 18, 2011 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, Jan. 25, to discuss fourth-quarter and full-year 2010 financial results. The meeting will be hosted by William C. Weldon, Chairman and Chief Executive Officer; Dominic J. Caruso, Vice President, Finance and Chief Financial Officer; and Louise Mehrotra, Vice President, Investor Relations. Investors and other interested parties may access...

HORSHAM, Pa., Dec. 29, 2010 /PRNewswire/ -- Centocor Ortho Biotech Inc. announced today that it has filed a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) requesting the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy. REMICADE was designated orphan drug status by the FDA on November 12, 2003...

HORSHAM, Pa., Dec. 20, 2010 /PRNewswire/ -- Centocor Ortho Biotech Inc. has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational drug abiraterone acetate administered with prednisone for the treatment of metastatic advanced prostate cancer in patients who have received prior chemotherapy containing a taxane. Janssen-Cilag International NV also filed a marketing authorization application (MAA) with the European Medicines Agency (EMA)...

Inspectors with the Food and Drug Administration (FDA) have discovered more issues at a Johnson & Johnson plant in Pennsylvania, according to a Reuters report published Wednesday.An FDA inspection report released late Wednesday evening revealed that a recent visit to the company's Fort Washington plant "uncovered multiple quality control problems, including a failure to properly handle customer complaints," the news agency is reporting.Furthermore, Reuters quotes the report as...

BURLINGTON, Mass., Dec. 7, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen/Pfizer's Enbrel is the leading tumor necrosis factor (TNF)-alpha inhibitor prescribed in newly diagnosed rheumatoid arthritis (RA) patients, outpacing Abbott's Humira in the first three lines of treatment. According to the upcoming Treatment Algorithms in Rheumatoid Arthritis report, two percent of newly...

BURLINGAME, Calif., Dec. 7, 2010 /PRNewswire/ -- Apexigen, Inc. announced today that it has entered into a collaboration and worldwide license agreement with Centocor Research & Development, Inc. and its affiliates to utilize Apexigen's proprietary therapeutic antibody technologies to discover and develop monoclonal antibody drugs. Apexigen will generate and screen antibodies to several targets specified by Centocor R&D, which will be responsible for development and...

The US Food and Drug Administration (FDA) has announced a recall of Mylanta and AlternaGel liquid antacids, making it the latest in a long line of Johnson & Johnson affiliated products to face a recall this year.The products, which are manufactured by Johnson & Johnson-Merck Consumer Pharmaceuticals, Co. (JJMCP), are being recalled due to a labeling issue. Each of the 12 varieties of Mylanta and the one version of AlternaGel affected by the notice contain a trace amount of alcohol...

BURLINGTON, Mass., Dec. 1, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although Amgen/Pfizer/Stiefel's Enbrel will remain the most-prescribed first-line biologic for moderate-to-severe psoriasis, it will lose market share at this line of therapy to agents in the IL-12/IL-23 inhibitors drug class, namely Centocor Ortho Biotech/Janssen-Cilag's Stelara. Surveyed U.S. dermatologists estimate...

HORSHAM, Pa., Dec. 1, 2010 /PRNewswire/ -- Acclaimed comedian and actor Jon Lovitz is talking candidly for the first time about living with severe plaque psoriasis through a national disease awareness campaign called Are You Serious?(TM). Psoriasis is a chronic autoimmune condition which causes red, scaly plaques on the skin and affects nearly 7.5 million Americans, including Lovitz, who struggled with the condition for 10 years before getting its symptoms under control. Through his...

An additional 9 million containers of Tylenol have been recalled by Johnson & Johnson because the painkiller does not adequately warn customers about the presence of trace amounts of alcohol used to flavor its products. The new recall follows the previous withdrawal of more than 200 million packages of Tylenol and Motrin, allergy treatment drug Benadryl and other brands that were removed from the market over the past year due to quality-control lapses. The latest debacle for J&J...